CRISPR

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade CRISPR 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CRSP

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. 

CEO
Samarth Kulkarni
CEOSamarth Kulkarni
Employees
Employees
Headquarters
Zug, Zug
HeadquartersZug, Zug
Founded
2013
Founded2013
Employees
Employees

CRSP Key Statistics

Market cap
4.61B
Market cap4.61B
Price-Earnings ratio
-7.69
Price-Earnings ratio-7.69
Dividend yield
Dividend yield
Average volume
1.72M
Average volume1.72M
High today
$48.66
High today$48.66
Low today
$47.09
Low today$47.09
Open price
$47.53
Open price$47.53
Volume
1.62M
Volume1.62M
52 Week high
$78.48
52 Week high$78.48
52 Week low
$44.12
52 Week low$44.12

Stock Snapshot

CRISPR(CRSP) stock is priced at $47.98, giving the company a market capitalization of 4.61B. It carries a P/E multiple of -7.69.

During the trading session on 2026-07-20, CRISPR(CRSP) shares reached a daily high of $48.66 and a low of $47.09. At a current price of $47.98, the stock is +1.9% higher than the low and still -1.4% under the high.

Trading volume for CRISPR(CRSP) stock has reached 1.62M, versus its average volume of 1.72M.

Over the past 52 weeks, CRISPR(CRSP) stock has traded between a high of $78.48 and a low of $44.12.

Over the past 52 weeks, CRISPR(CRSP) stock has traded between a high of $78.48 and a low of $44.12.

CRSP News

Simply Wall St 2d
CRISPR Therapeutics Is Down 10.4% After EPS, Revenue Expectations Diverge From Valuation Concerns - simplywall.st

...

CRISPR Therapeutics Is Down 10.4% After EPS, Revenue Expectations Diverge From Valuation Concerns - simplywall.st
TipRanks 4d
Crispr Therapeutics Expands Autoimmune Pipeline With New CTX112 Trial

Crispr Therapeutics (CRSP) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the index of...

Analyst ratings

58%

of 24 ratings
Buy
58.3%
Hold
41.7%
Sell
0%

People also own

Based on the portfolios of people who own CRSP. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.